Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Discussion This study provides new insights into the evolving role of GLP-1 RAs in healthcare, particularly how their use amongst people with overweight or obesity coincides with first-time diagnoses of type 2 diabetes, sleep apnea, and cardiovascular disease
Common side effects shared by both medications: Nausea (most common, usually transient peaks during dose escalation) Vomiting Diarrhea or constipation Decreased appetite and early satiety Bloating or stomach discomfort Injection site reactions Key safety warnings that apply to both drugs: FDA Boxed Warning (both): Possible risk of thyroid C-cell tumors, based on animal studies
Ideal candidates for semaglutide weight loss programs typically have a body mass index over 30, or a BMI of 27 with associated medical conditions like hypertension, type 2 diabetes, or elevated cholesterol
Realistic expectation levels and understanding of treatment limitations contribute to higher satisfaction rates
